Prevalence of HTLV-III/LAV in household contacts of patients with confirmed AIDS and controls in Kinshasa, Zaire. 1986

J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran

Household members of 46 patients with confirmed acquired immunodeficiency syndrome (AIDS) and 43 human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV)-seronegative controls from Kinshasa, Zaire, were identified and sought for serologic testing for evidence of HTLV-III/LAV infection. Twenty (9.8%) of 204 case-household members and three (1.9%) of 155 control-household members were HTLV-III/LAV seropositive (relative risk = 5.1; 95% confidence interval, 1.7 to 15.2). Eleven (61.1%) of 18 spouses of patients with AIDS were HTLV-III/LAV seropositive, compared with one (3.7%) of 27 control spouses (relative risk = 16.5; 95% confidence interval, 3.7 to 75.0). Except for spouses, the rate of HTLV-III/LAV seropositivity did not differ significantly between case and control households. Furthermore, for adults in case households who were not spouses, the number seropositive for HTLV-III/LAV was identical to that predicted from sex- and age-specific HTLV-III/LAV seroprevalence rates. These data from Zaire confirm the results of US and European studies of household contacts of infected hemophiliacs and pediatric patients with AIDS.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005190 Family A social group consisting of parents or parent substitutes and children. Family Life Cycles,Family Members,Family Life Cycle,Family Research,Filiation,Kinship Networks,Relatives,Families,Family Member,Kinship Network,Life Cycle, Family,Life Cycles, Family,Network, Kinship,Networks, Kinship,Research, Family
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies

Related Publications

J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
July 1986, The New England journal of medicine,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
February 1986, The New England journal of medicine,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
April 1986, JAMA,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
September 1985, Blood,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
June 1986, JAMA,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
July 1986, Quintessenz Journal,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
January 1986, Pennsylvania medicine,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
January 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
January 1986, JAMA,
J M Mann, and T C Quinn, and H Francis, and N Nzilambi, and N Bosenge, and K Bila, and J B McCormick, and K Ruti, and P K Asila, and J W Curran
January 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene,
Copied contents to your clipboard!